EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders

Ewelina Russjan iD, Dominika Zając iD, Katarzyna Kaczyńska iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27135803 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ewelina Russjan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiration Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawińskiego 5, 02-106 Warsaw, Poland. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted in response to food intake that acts biologically by binding to GLP-1 receptors. The primary function of GLP-1 is to stimulate insulin secretion and inhibit glucagon secretion, which helps limit after-meal spikes in blood glucose. GLP-1 reduces intestinal contractility, slows down gastrointestinal motility and emptying, and also acts directly on the hypothalamus, thereby regulating appetite and food intake. Due to its metabolic effects, GLP-1 forms the basis of medications currently used to treat type 2 diabetes (T2DM) and obesity. However, it has also been observed that the use of GLP-1 agonists in the treatment of obesity or diabetes has a beneficial effect on comorbid respiratory conditions. This narrative review analyzes the scientific literature and describes the most recent information on the impact of GLP-1 receptor agonist (GLP-1 RA) therapies on the most common respiratory disorders—both the beneficial and undesirable effects. We discuss evidence that acute lung injury, COVID-19, pulmonary fibrosis, asthma, chronic obstructive pulmonary disease (COPD), and obstructive sleep apnea can benefit from therapies with various GLP-1 RAs. They can complement existing lung-targeted treatments, but as research progresses, they are likely to play an ever more important role in the treatment of respiratory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsHumansPulmonary Disease, Chronic ObstructiveGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide 1AnimalsCOVID-19AsthmaPulmonary FibrosisSleep Apnea, ObstructiveSARS-CoV-2

Stichwörter der Autor:innen

ALI/ARDSCOPDCOVID-19GLP-1OSAasthmapulmonary fibrosisrespiratory disorders

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide 1

Autor:innen und Institutionen

  • Department of Respiration Physiology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawińskiego 5, 02-106 Warsaw, Poland.

ORCID-Profile: Ewelina Russjan, Dominika Zając, Katarzyna Kaczyńska

Zitieren

APA

Russjan, E., Zając, D., & Kaczyńska, K. (2026). Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27135803

Vancouver

Russjan E, Zając D, Kaczyńska K. Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27135803

BibTeX
@article{Russjan2026,
  author = {Russjan, Ewelina and Zając, Dominika and Kaczyńska, Katarzyna},
  title = {Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27135803}
}
Kostenlos starten →